CCL3 and lymphoma: Therefore, maintained cytokine production in the presence of ibrutinib owing to the C481S mutation suggests that CCL3 and CCL4 may shape a supportive lymphoma microenvironment and thus contribute to in vivo selection of malignant B cells that express mutant BTK [8].